Amgen Non Current Liabilities Total from 2010 to 2024

AMGN Stock  USD 294.00  0.53  0.18%   
Amgen Non Current Liabilities Total yearly trend continues to be very stable with very little volatility. Non Current Liabilities Total is likely to grow to about 76.2 B this year. During the period from 2010 to 2024, Amgen Non Current Liabilities Total quarterly data regression pattern had sample variance of 323835633.2 T and median of  37,199,000,000. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
1986-03-31
Previous Quarter
63.5 B
Current Value
63 B
Quarterly Volatility
19.8 B
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 3 B or Selling General Administrative of 5.8 B, as well as many indicators such as Price To Sales Ratio of 9.47, Dividend Yield of 0.0185 or PTB Ratio of 25.96. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Check out the analysis of Amgen Correlation against competitors.

Latest Amgen's Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Amgen Inc over the last few years. It is Amgen's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amgen's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Amgen Non Current Liabilities Total Regression Statistics

Arithmetic Mean39,790,393,333
Geometric Mean23,080,759,965
Coefficient Of Variation45.23
Mean Deviation11,495,299,556
Median37,199,000,000
Standard Deviation17,995,433,678
Sample Variance323835633.2T
Range76.1B
R-Value0.86
Mean Square Error91699006.6T
R-Squared0.74
Significance0.000042
Slope3,454,609,643
Total Sum of Squares4533698865.5T

Amgen Non Current Liabilities Total History

202476.2 B
202372.5 B
202245.8 B
202142.3 B
202041.9 B
201937.2 B
201840.4 B

About Amgen Financial Statements

Amgen investors utilize fundamental indicators, such as Non Current Liabilities Total, to predict how Amgen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Total72.5 B76.2 B

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.61A Agilent TechnologiesPairCorr
  0.8ME 23Andme HoldingPairCorr
  0.73VALN Valneva SE ADRPairCorr
  0.81JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Amgen Stock

  0.49MDGL Madrigal PharmaceuticalsPairCorr
  0.42RNXT RenovoRxPairCorr
  0.41KZR Kezar Life SciencesPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.621
Dividend Share
8.88
Earnings Share
7.83
Revenue Per Share
60.641
Quarterly Revenue Growth
0.232
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.